Rockwell Medical Stock (NASDAQ:RMTI)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$1.04

52W Range

$0.86 - $5.15

50D Avg

$1.49

200D Avg

$2.40

Market Cap

$35.08M

Avg Vol (3M)

$269.56K

Beta

1.62

Div Yield

-

RMTI Company Profile


Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

244

IPO Date

Jan 27, 1998

Website

RMTI Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 24Dec 23Dec 22
Drug Revenue$46.00K$2.34M-
Concentrate Products$101.44M$81.27M-
Upfront Fee--$2.50M

Fiscal year ends in Dec 24 | Currency in USD

RMTI Financial Summary


Dec 24Dec 23Dec 22
Revenue$101.49M$83.61M$72.81M
Operating Income$608.00K$-6.67M$-16.78M
Net Income$-480.00K$-8.44M$-20.58M
EBITDA$608.00K$-4.69M$-16.17M
Basic EPS$-0.02$-0.36$-2.09
Diluted EPS$-0.02$-0.36$-2.09

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts


Q4 24Mar 20, 25 | 8:00 AM
Q3 24Nov 12, 24 | 8:00 AM
Q2 24Aug 08, 24 | 8:00 AM

Peer Comparison


TickerCompany
BFRIBiofrontera Inc.
PROCProcaps Group S.A.
CPIXCumberland Pharmaceuticals Inc.
ITCIIntra-Cellular Therapies, Inc.
LFCRLifecore Biomedical, Inc.
EVOKEvoke Pharma, Inc.
SXTCChina SXT Pharmaceuticals, Inc.
ANIPANI Pharmaceuticals, Inc.
AQSTAquestive Therapeutics, Inc.
IXHLIncannex Healthcare Limited
COLLCollegium Pharmaceutical, Inc.
RGCRegencell Bioscience Holdings Limited
PAHCPhibro Animal Health Corporation
KMDAKamada Ltd.